GlassScriptPhysician profile
Jeffrey W Kienzle
NPI 1073545471
$8,566.48
in general payments reported to CMS, 2019-2025
30 companies · $3,549 in 2025
The $3,549 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,088 · 2022: $575 · 2023: $1,165 · 2024: $2,189 · 2025: $3,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,555 · Travel and Lodging: $1,163 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,554.86 |
| Travel and Lodging | $1,163.42 |
| Education | $185.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,910.11 | 2021-2025 | Airsupra, Fasenra, Tezspire |
| Inspire Medical Systems, INC. | $1,595.50 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $922.35 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $802.13 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Insmed, INC. | $454.38 | 2021-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $382.32 | 2021-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $365.85 | 2021-2025 | Stiolto Respimat, Jascayd |
| Regeneron Healthcare Solutions, INC. | $361.87 | 2021-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $264.76 | 2022-2025 | Winrevair, Zerbaxa, Recarbrio |
| Genzyme Corporation | $215.56 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $204.99 | 2021-2024 | Xarelto |
| Electromed, INC. | $204.80 | 2021-2025 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $140.44 | 2021-2024 | |
| Grifols USA, LLC | $106.56 | 2021-2022 | |
| Verona Pharma, INC. | $105.99 | 2025 | Ohtuvayre |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $88.20 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $81.40 | 2021-2024 | Glassia |
| Baxter Healthcare | $75.79 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Inogen, INC. | $50.60 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Resmed Corp | $37.31 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $27.41 | 2021-2022 | |
| Pulmonx Corporation | $26.27 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Itamar Medical INC | $24.49 | 2025 | Watchpatone |
| Tactile Systems Technology INC | $22.62 | 2024 | Entre Plus, Flexitouch Plus |
| Mallinckrodt Hospital Products INC. | $20.65 | 2023 | Terlivaz |
| Philips North America LLC | $16.96 | 2021 | |
| Harmony Biosciences LLC | $16.41 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.82 | 2021 | |
| Nabriva Therapeutics, Plc | $14.72 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Kienzle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.